↓ Skip to main content

S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

Overview of attention for article published in BMC Musculoskeletal Disorders, February 2004
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)

Mentioned by

blogs
1 blog
twitter
10 tweeters
facebook
4 Facebook pages
wikipedia
1 Wikipedia page
reddit
1 Redditor

Citations

dimensions_citation
89 Dimensions

Readers on

mendeley
50 Mendeley
citeulike
1 CiteULike
Title
S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]
Published in
BMC Musculoskeletal Disorders, February 2004
DOI 10.1186/1471-2474-5-6
Pubmed ID
Authors

Wadie I Najm, Sibylle Reinsch, Fred Hoehler, Jerome S Tobis, Phillip W Harvey

Abstract

S-adenosylmethionine (SAMe) is a dietary supplement used in the management of osteoarthritis (OA) symptoms. Studies evaluating SAMe in the management of OA have been limited to Non Steroidal Anti-inflammatory Drugs (NSAIDs) for comparison. The present study compares the effectiveness of SAMe to a cyclooxygenase-2 (COX-2) inhibitor (celecoxib) for pain control, functional improvement and to decrease side effects in people with osteoarthritis of the knee.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Italy 1 2%
Unknown 48 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 24%
Student > Bachelor 7 14%
Student > Master 7 14%
Other 5 10%
Unspecified 4 8%
Other 15 30%
Readers by discipline Count As %
Medicine and Dentistry 20 40%
Agricultural and Biological Sciences 13 26%
Unspecified 5 10%
Biochemistry, Genetics and Molecular Biology 3 6%
Psychology 3 6%
Other 6 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2019.
All research outputs
#941,453
of 13,603,280 outputs
Outputs from BMC Musculoskeletal Disorders
#205
of 2,685 outputs
Outputs of similar age
#11,780
of 150,381 outputs
Outputs of similar age from BMC Musculoskeletal Disorders
#1
of 1 outputs
Altmetric has tracked 13,603,280 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,685 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 150,381 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them